Objective: To define the clinical features and biomarkers that predict which patients with pure autonomic failure will develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy. Methods: One hundred patients who presented with pure autonomic failure were recruited at 5 medical centers in the United States. Seventy-four patients agreed to be followed prospectively. Patients underwent clinical evaluations including neurological rating scales, sleep questionnaires, smell test, and sympathetic and parasympathetic cardiovascular autonomic function tests. Results: At enrollment, patients were 68 6 12 years old (median 6 interquartile range) and had had autonomic failure for 5 6 7 years. Within 4 years of follow-up, 25 of 74 subjects (34%) developed dementia with Lewy bodies (n 5 13), Parkinson disease (n 5 6), or multiple system atrophy (n 5 6). The presence of probable rapid eye movement (REM) sleep behavior disorder was strongly associated with the development of a manifest central nervous system (CNS) synucleinopathy (odds ratio 5 7.1). Patients who phenoconverted to multiple system atrophy had younger age at onset of autonomic failure, severe bladder/bowel dysfunction, preserved olfaction, and a cardiac chronotropic response upon tilt > 10 beats per minute. Those who phenoconverted to Parkinson disease or dementia with Lewy bodies had decreased olfaction, a lesser chronotropic response to tilt, and a longer duration of illness. The small group of patients retaining the pure autonomic failure phenotype had very low plasma norepinephrine levels, slow resting heart rate, no REM sleep behavior disorder, and preserved smell. Interpretation: Patients presenting with pure autonomic failure are at high risk of phenoconverting to a manifest CNS synucleinopathy. Specific clinical features predict future diagnosis.
feature receive a diagnosis of pure autonomic failure (PAF). 4 After a period of time, in some patients, motor or cognitive deficits emerge, indicating that additional neuronal populations in the central nervous system (CNS) are affected, and patients are diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA). 5, 6 Whether PAF is a specific synucleinopathy mostly restricted to autonomic neurons or is always an early premotor or precognitive phase of a widespread CNS disorder is unknown. PAF was first described by Bradbury and Eggleston in 1925. Their original report featured 3 middle-aged men with orthostatic hypotension, a slow unchanging pulse rate, constipation, decreased sweating, and erectile dysfunction. 7 The authors suspected that their subjects' symptoms were the result of chronic failure of the autonomic nervous system. Since then, a number of clinical and neuropathological studies of similar patients have been reported, all showing degeneration of peripheral autonomic neurons and the aggregation of a-Syn in Lewy bodies within sympathetic ganglia and Lewy neurites along autonomic axons in the heart, periadrenal tissue, bladder, skin, and colon. [8] [9] [10] [11] [12] [13] Sparse Lewy bodies were also found in the substantia nigra and locus coeruleus but without neuronal loss, which explained the lack of motor abnormalities. 8, 10, [14] [15] [16] [17] This pathological hallmark tied PAF to PD and DLB, leading to its classification as a synucleinopathy without manifest CNS involvement.
It is well known that some patients with PAF will develop PD, DLB, or MSA, but phenoconversion rates from PAF to a manifest CNS synucleinopathy are lacking. In the general population, hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD) have been linked to a-Syn-driven neurodegeneration, 18 and carry an increased risk for a future diagnosis of PD or DLB. 19, 20 The prognostic implications of autonomic failure combined with these established risk factors are unknown, and predictors of phenoconversion to MSA have yet to be determined. We conducted a multicenter prospective study of patients presenting with PAF to define the clinical characteristics of a national cohort, determine phenoconversion rates to PD, DLB, and MSA, and identify the clinical features and biomarkers that may predict phenoconversion.
Patients and Methods

Subjects
Participants were recruited through the Autonomic Disorders Consortium, a multicenter collaborative study supported by the NIH Rare Disease Clinical Research Network (RDCRN).
Subjects were enrolled in a prospective longitudinal observational natural history study at 5 U.S. medical centers: New York University Medical Center (New York, NY), Vanderbilt University (Nashville, TN), Mayo Clinic (Rochester, MN), NIH Intramural Research Program (Bethesda, MD), and Beth Israel Deaconess Medical Center (Boston, MA). Sites were selected for their expertise in autonomic research in neurological diseases. The protocol was developed with NIH program directors within the RDCRN. Approval for the study procedures was obtained from each local institutional review board, and informed consent was obtained in all cases. To standardize autonomic testing and data acquisition across sites, a manual of operations describing the study procedures was developed. Training videos developed by the consortium were made available to ensure standardization of the clinical assessments and neurological rating scales. Source data were collected in customdesigned case report forms and captured electronically using a secure Research Electronic Data Capture (RedCap) platform.
Subjects were recruited from September 2011 to September 2015. As inclusion criteria, patients with autonomic failure were required to have neurogenic orthostatic hypotension defined as (1) a fall in blood pressure (BP) of 20mmHg systolic or 10mmHg diastolic within the first 3 minutes of upright tilt 21 ; and (2) absence of phase IV BP overshoot after release of the Valsalva strain, consistent with sympathetic (autonomic) failure and a neurogenic cause. 22 The main exclusion criteria were (1) fulfillment of diagnostic clinical criteria for PD, 23 MSA, 24 DLB, 25 or other neurodegenerative disorders; (2) presence of a peripheral neuropathy, amyloidosis, diabetes, or autoimmune disease, including seropositivity for antibodies against the ganglionic acetylcholine receptor; and (3) other secondary causes of orthostatic hypotension, including medications, dehydration, or severe anemia. Evaluations took place at 12-month intervals.
Study Assessments
AUTONOMIC FUNCTION TESTS. At each study visit, subjects underwent a standard battery of autonomic function tests, in a quiet, temperature-controlled room. Participants were free of caffeine, alcohol, and nicotine from the previous evening. An intravenous forearm catheter was inserted into the antecubital vein, and subjects were transferred to the tilt table for instrumentation. Continuous electrocardiographic RR intervals were recorded from 3 precordial electrodes. Beat-to beat BP was measured with finger plethysmography with the hand supported at heart level. BP was also measured at 1-minute intervals with a validated automated cuff sphygmomanometer over the brachial artery. All signals were acquired and digitized and sampled at a minimum rate of 500Hz. As a measure of parasympathetic function, subjects were verbally coached to breathe at 6 cycles per minute, and respiratory sinus arrhythmia during deep paced breathing was calculated from the average of the 3 longest RR intervals during expiration divided by the average of the 3 shortest RR intervals during inspiration (ie, expiratory:inspiratory ratio). 22 A 300-second segment of spontaneous breathing in the supine position was selected and processed to detect RR intervals. Heart rate variability in the time and frequency domain were measured following standards. 26 Subjects performed a standardized Valsalva maneuver, maintaining an expiratory pressure of >30mmHg for at least 10 seconds. If BP was not higher than baseline within 10 seconds after release of the Valsalva strain (ie, phase IV), the overshoot in BP was considered absent, indicative of sympathetic (autonomic) failure. Pressure recovery time was measured as the time (in seconds) taken for the systolic BP to return to baseline values after release of the strain. 27 After the subject had fully recovered, BP and RR intervals were acquired for a further 10 minutes. While the subject was still supine, venous blood was sampled through the indwelling catheter. Subjects were then tilted upright to an angle of 60 8 and instructed to remain immobile. After subjects had been tilted upright for 10 minutes, a second set of blood samples were acquired to assay plasma norepinephrine levels using highperformance liquid chromatography with electrochemical detection. Patients also underwent a complete blood count, comprehensive metabolic panel, and urinalysis.
NEUROLOGICAL ASSESSMENTS. All patients had a full neurological evaluation captured in case report forms. In addition, to monitor the emergence of motor/cognitive deficits, all patients were evaluated with disease-specific rating scales for PD and MSA, including Hoehn and Yahr, 28 and the Unified Multiple System Atrophy Rating Scale (UMSARS). 29 32 was administered in a controlled wellventilated setting.
AUTONOMIC SYMPTOM ASSESSMENT AND DISABILITY.
The severity of symptoms of orthostatic hypotension and impact on activities of daily living was assessed using the Orthostatic Hypotension Questionnaire, a 10-item patientreported outcome. 33 Symptoms of generalized autonomic dysfunction were assessed using COMPASS (Composite Autonomic Symptom Scale), which has 46-questions addressing orthostatic, vasomotor, sudomotor, pupillomotor, urinary, and sleep function. 34 The degree of disability was rated using the UMSARS disability domain (part IV).
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DIAGNOSTIC OUTCOMES. At each 12-month interval follow-up visit, the diagnosis of the subject was re-evaluated to determine whether he/she retained a PAF phenotype or had developed clinical evidence of PD, DLB, or MSA according to current consensus criteria. [23] [24] [25] The diagnosis of PAF remained if there was persistence of autonomic failure, in the absence of significant motor or cognitive deficits. 4 
Data Analysis and Definitions
All data were reviewed, verified, and audited by the RDCRN's designated Data Monitoring and Coordinating Center. Outlying data points were flagged and discussed with investigators through email and monthly conference calls. Categorical variables were compared using the chi-square test. For comparison of quantitative dependent variables, appropriate parametric tests were used (see table legends). Symptom onset was defined as the date the patient first noticed symptoms of orthostatic hypotension (eg, dizziness, light-headedness, feeling about to faint, or syncope when upright). Hypertension was defined as BP > 140/90mmHg 35 and bradycardia defined as a heart rate < 60bpm. Anemia was defined as hemoglobin < 13g/dl in men, and < 12g/dl in women, according to the World Heath Organization criteria. 36 Cardiac baroreflex gain was assessed during the Valsalva maneuver and determined by calculating the slope of the regression line relating changes in systolic BP against RR intervals and expressed as milliseconds per millimeter of mercury, as described. 37 The risk of developing a manifest CNS synucleinopathy in the 74 subjects from the cohort was estimated with the Kaplan-Meier method. Disease-free survival rate was assessed from the date of initial orthostatic symptoms to the date of the diagnosis of manifest CNS synucleinopathy or to the last follow-up visit for censored observations (subjects who died or were lost to follow-up). Several markers were examined to determine the odds ratio of developing a manifest CNS synucleinopathy. Missing data were managed using multiple imputation. Analysis using this method has been shown to provide less biased estimates of associations than the use of complete data only or other methods such as mean imputation. 38 Data were analyzed with SPSS v19.0 (IBM, Armonk, NY) and Prism (GraphPad Software, La Jolla, CA). Data are expressed as median 6 interquartile range (IQR) unless otherwise specified.
Role of the Funding Source
Funds from the NIH supported the U.S. Autonomic Disorders Consortium. Members of the consortium were involved in the study design, conduct, database development, and data collection. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Patient Characteristics at Entry
One hundred consecutive patients met inclusion criteria and completed the clinical evaluations at entry into the natural history study (Supplementary Table) . A significant majority of subjects were males (70% vs 30%, chisquare p 5 0.0038). Symptoms of neurogenic orthostatic hypotension began at age 63 6 14 years. At the time of enrollment, median duration of illness was 5 6 7 years. Symptoms of orthostatic hypotension were the main complaint at the time of enrollment; 97% of patients reported having had symptoms of orthostatic hypotension within the past week on the Orthostatic Hypotension Questionnaire. 33 Additional symptoms of autonomic impairment included constipation (58%), bladder disturbances (50%), sweating abnormalities (44%), and erectile dysfunction in men (65%). The most commonly prescribed medications were midodrine (64%), fludrocortisone (45%), and pyridostigmine (11%).
Autonomic function testing confirmed that all patients met criteria for autonomic failure. 21 Resting supine BP was 152/84mmHg (IQR 5 15/10), and the prevalence of supine hypertension was 47%. Supine heart rate was 65 6 5bpm, with 13% of patients having resting bradycardia (<60bpm). After 3-minutes of upright tilt, BP fell by 252 6 27mmHg systolic and 223 6 23 mmHg diastolic, and standing BP was 93/58 mmHg (IQR 5 34/23). BP continued to fall with prolonged tilt.
Markers of Sympathetic Function
At the end of the straining phase of the Valsalva maneuver, BP had fallen by 262 6 26mmHg systolic and 217 6 12mmHg diastolic. Late phase II rebound was absent in all patients. Despite the pronounced fall in BP, heart rate increased by only 8 6 8bpm. Cardiac baroreflex gain (estimated by the slope of the relationship between changes in BP and RR intervals) was 1.8 6 0.2ms/mmHg, a value significantly lower than in normal controls. 39 The phase IV overshoot in BP was absent in all cases. Ten seconds after release of the strain, systolic BP remained 29 6 24mmHg lower than at baseline. The latency of the Valsalva pressure recovery time was 32 6 25 seconds, a value much longer than in normal subjects. 40 These markers are consistent with impaired baroreflex-mediated sympathetic activation.
On average, plasma norepinephrine levels in the supine position were lower than expected for age at 101 6 97pg/ml, and the increase in plasma norepinephrine levels after head-up tilt was blunted (54%, 191 6 218pg/ml), findings consistent with reduced sympathetic activity. 22 A subset of patients had norepinephrine levels that remained <100pg/ml both supine and upright (n 5 18).
Markers of Parasympathetic Function
Seven patients had a cardiac pacemaker, and 80% had normal sinus rhythm, allowing parasympathetic function to be determined. During deep paced breathing, the shortest RR intervals during inspiration were 855 6 136 milliseconds and the longest RR intervals during expiration were 937 6 152 milliseconds, resulting in an E:I ratio of 1.07 6 1.12; 71% of patients had an E:I ratio that was below the value expected for their age. Spectral measures of heart rate variability in the high-frequency range during a 300-second segment of spontaneous breathing were 58 6 81 milliseconds. 2 Measures of heart rate variability in the time domain were also reduced; root mean square of successive differences in RR intervals was 16 6 12 milliseconds, and the percentage of neighboring RR intervals that differed by 50 milliseconds (pNN50) was only 13 6 21%. Taken together, these multiple markers of parasympathetic (vagal) influences on the sinoatrial node induced by respiration were universally reduced in all patients.
Clinical Laboratory Findings
Clinical laboratory tests were consistent with mild anemia in 47% of patients. Median hemoglobin was 13.1 6 1.7mg/dl and hematocrit was 39 6 5%. Serum creatinine concentration was 1.15 6 0.38mg/dl with a blood urea nitrogen level of 21 6 9mg/dl. Proteinuria was present in 25% (19 of 75) of subjects. Proteinuria was graded as mild in 20% of patients (10-20mg/dl), moderate in 3% (1-30mg/dl), and severe in 1% (30-100mg/dl).
Neurological Features
On entry, none of the patients had signs of cognitive impairment. MMSE score was normal (29 6 1 points). Hoehn and Yahr motor assessments were rated at 0 with no signs of disease, and investigators rated 85% of patients as completely independent on UMSARS part IV. Although none of the patients met clinical diagnostic criteria for PD, MSA, or DLB, close review of the diseasespecific rating scales revealed the presence of subtle nonspecific neurological deficits. These included mild generalized slowness/bradykinesia (12%), minimal hypomimia or reduced blinking frequency (26%), reduced unilateral arm swing when walking (12%), and mild slowing/ reduction in amplitude in rapid alternating movements (22%). None of the patients had resting tremor or rigidity.
Sleep Disturbances
Overall, 24% of patients reported difficulty falling asleep. Ninety-seven percent of patients had difficultly remaining asleep because of nocturia, which awoke them 3 6 1 times during the night. The prevalence of probable RBD at study entry was 72%. During sleep, 56% of patients shouted, yelled, or swore, 33% confessed to having hurt either themselves or their bed partner while sleeping, and 32% reported having fallen out of bed at night. Sixteen percent of patients had a diagnosis of sleep apnea.
Olfactory Function
Only 4 patients subjectively complained of lack of smell. However, only 19% of patients had normal olfactory testing (UPSIT > 34 points), whereas 8% had mild microsmia (UPSIT 5 30-33 points), 6% had moderate microsmia (UPSIT 5 26-29 points), 23% had severe microsmia (UPSIT 5 19-25), and 44% had total anosmia (UPSIT < 18).
Outcomes at Follow-up Seventy-four patients agreed to be followed longitudinally (Fig 1) . Age, gender distribution, and clinical features of these 74 patients were similar to the 26 who declined to be followed up, suggesting a random selection. Of the 74 patients who agreed to the yearly assessments, 2 died, and 1 declined to continue in the study. Therefore, 1-year follow-up data were available in 71 cases (96%). Of these 71, 11 patients were diagnosed with a manifest CNS synucleinopathy: 2 with PD, 4 with DLB, and 5 with MSA. This represents a 15% rate of phenoconversion.
Of the 60 remaining patients, 3 declined to continue in the study, and 12 were not yet due for their 2-year visit. Therefore, 2-year data were available in 45 cases (60%). At that time, 6 more cases had been diagnosed with a manifest CNS synucleinopathy: 1 with PD, 4 with DLB, and 1 with MSA. This represents a 13% rate of phenoconversion.
Of the 40 remaining patients, 1 died, and 8 were not yet due for the 3-year visit. Therefore, 3-year followup data were available in 31 cases (42%). Of these, 4 patients were diagnosed with a manifest CNS synucleinopathy: 2 with PD and 2 with DLB, representing a 13% phenoconversion rate.
Finally, of the 27 remaining patients, 12 were not due for their 4-year follow-up visit. Therefore, 4-year follow-up data were available in 15 cases (20%). Of these, 4 additional cases had developed a manifest CNS synucleinopathy: 1 with PD and 3 with DLB, representing a 27% phenoconversion rate.
The cumulative incidence of phenoconversion during the 4-year period was 34%. Figure 2 shows a Kaplan-Meier survival curve from the time of first symptom of neurogenic orthostatic hypotension to the time of diagnosis of a manifest synucleinopathy. The clinical and autonomic features of the 25 patients who phenoconverted to a manifest CNS synucleinopathy are detailed in Table 1 .
Patients Retaining the PAF Phenotype
Of the 42 patients who still had a diagnosis of PAF at their last evaluation (12 at the 1-year evaluation, 7 at the 2-year evaluation, 12 at the 3-year evaluation, and 11 at the 4-year evaluation), 30 had additional nonspecific features suggesting CNS involvement (ie, probable RBD, impaired olfaction, and/or subtle motor signs). Only 12 subjects with PAF remained completely free of signs suggesting CNS involvement (Table 2 ). These patients were 57 6 12 years old when their symptoms of neurogenic orthostatic hypotension first began and had a disease duration of 6 6 5 years, and their plasma norepinephrine levels were very low (median 5 63 6 37pg/ml; in all cases, < 110pg/ml). Skin biopsy in 1 of these cases showed a-Syn deposition in autonomic nerves, as described. 41 
Clinical Predictors of Phenoconversion
PHENOCONVERSION TO PD OR DLB. All patients with PAF who went on to develop manifest PD or DLB had impaired olfactory function. All except for 1 had probable RBD at study entry. Age at onset of symptomatic orthostatic hypotension was 65 6 11 years, and they received a diagnosis of PD/DLB 9.5 6 7.5 years later. Constipation and urinary symptoms were mild and occasional, and did not require treatment (see Table 1 ). Careful review of their neurological examination showed subtle motor signs of CNS involvement emerging (including mild bradykinesia, minimal hypomimia/ reduced blinking, mildly reduced unilateral arm swing, and mild slowing/reduction in amplitude in rapid alternating movements) at the entry visit. Supine resting heart rate was 63 6 7bpm (in all cases, < 78bpm), and the increase in heart rate after 3 minutes of upright tilt was 15 6 8 (in all cases, < 11bpm). Supine resting plasma norepinephrine levels were 118 6 66pg/ml (in all cases, < 230pg/ml). PHENOCONVERSION TO MSA. All patients diagnosed with MSA on follow-up had probable RBD at the time of entry. In contrast to those who developed PD or DLB, they all had preserved olfactory function (UPSIT score > 30 in all cases). Compared to patients who phenoconverted to PD/DLB, onset of symptomatic neurogenic orthostatic hypotension in MSA patients occurred at a younger age (52 6 11 years, p 5 0.009), and the median time to diagnosis was shorter (5 6 3.5 years, p 5 0.017). Constipation and urinary symptoms were moderate or severe and required treatment. Supine resting heart rate was higher at 71 6 3bpm (phenoconverters to MSA vs PD/DLB, p 5 0.041), and the increase in heart rate after 3 minutes of head-up tilt was higher (12 6 3bpm; in all cases > 10bpm; phenoconverters to MSA vs PD/DLB, p 5 0.0001). Supine resting plasma norepinephrine was 325 6 163pg/ml (in all phenoconverters to MSA, >133pg/ml; vs PD/DLB phenoconverters, p 5 0.026). Figure 3 depicts the relationship between olfaction, plasma norepinephrine levels in the supine position, and heart rate response after 3 minutes of head-up tilt in each diagnostic group.
Risk Prediction for Phenoconversion
In patients with PAF, the presence of probable RBD was strongly associated with phenoconversion to a manifest CNS synucleinopathy (odds ratio Autonomic risk factors were also examined. A supine heart rate > 70bpm combined with a supine plasma norepinephrine level > 110pg/ml was associated with future risk of MSA (OR 5 18, 95% CI 5 1.9-66). A supine heart rate < 70bpm and heart rate response to tilt < 10bpm were associated with phenoconversion to PD/DLB (OR 5 4.8, 95% CI, 1.4-16). The likelihood of retaining the PAF phenotype was higher in those with a supine heart rate < 70bpm and supine plasma norepinephrine levels < 110pg/ml (OR 5 5, 95% CI 5 1.6-18).
Discussion
We found that, within 4 years of enrollment in this prospective natural history study, 34% of patients with PAF phenoconverted to a manifest CNS synucleinopathy, either to DLB (18%), to PD (8%), or to MSA (8%). Phenoconversion best describes this change in clinical features because it is due to anatomical spread of a pathology that was already present at the time of enrollment. The risk of phenoconversion from PAF to a manifest CNS synucleinopathy was around 14% per year.
Almost all patients who phenoconverted had RBD at the time of enrollment, 88% had subtle motor deficits, and 53% had olfactory loss, all symptoms previously reported to predict phenoconversion in premotor PD cohorts. 18, 19, [42] [43] [44] [45] Therefore, the presence of RBD, olfactory loss, or subtle motor deficits should be considered as nonsupportive features of PAF, because their presence indicate that CNS neurons are already affected, and thus the disease is not exclusively autonomic and is likely to progress. The diagnostic criteria of PAF should therefore be modified to reflect these findings. A stepwise clinical progression, observed in our cohorts and others, 46 appears to be a characteristic feature of synucleinopathies, conceivably due to prion-like spreading. 1, 2 After the onset of symptomatic neurogenic orthostatic hypotension, it took a median of 5 years to develop the motor deficits leading to the diagnosis of MSA, and nearly twice as long (9.5 years) to diagnose PD or DLB. The postmortem pathological findings in patients with PAF are very similar to those described in cases of incidental Lewy body disease. 47 Whether cases of incidental Lewy body disease had symptoms of autonomic failure during life is unknown. Of the 42 patients who remained as PAF at their last clinical evaluation, 30 had RBD, impaired olfaction, or subtle motor signs suggesting that synuclein-driven neurodegeneration was already present in their CNS and will likely spread further, resulting in phenoconversion. In contrast, 12 of these patients had neither RBD, olfactory loss, nor subtle motor deficits, implying that they have a restricted synucleinopathy affecting only autonomic neurons. In both groups, there were more men than women, but patients without CNS findings were younger (median 5 57 vs 69 years old). A distinctive feature of this small group was a very low plasma norepinephrine concentration, with levels <110pg/ml in all patients, indicating a degree of peripheral sympathetic neuronal degeneration significantly more pronounced than in those who phenoconverted.
RBD and preserved olfaction in a patient with PAF increased the likelihood of a future diagnosis of MSA, whereas olfactory loss increased the odds of developing PD/DLB. Autonomic features were also useful premotor diagnostic clues. Plasma norepinephrine levels tended to be lower in patients who phenoconverted to PD/DLB and were higher in those who phenoconverted to probable MSA. Previous studies of heart rate in patients with synucleinopathies have been contradictory. 48, 49 In our prospective cohort, we found heart rate to be useful for predicting phenoconversion; a lower resting heart rate and a very reduced heart rate increase of <10bpm, despite the fall in BP, increased the risk of phenoconverting to PD or DLB, a finding consistent with selective cardiac sympathetic denervation in patients with Lewy body diseases. 50, 51 Conversely, a resting heart rate >70bpm and a better preserved chronotropic response to tilt were associated with future risk of phenoconversion to MSA, which is consistent with spared sympathetic innervation to the heart in these patients. Parasympathetic denervation of the heart was a feature of all patients with synucleinopathies, resulting in reduced heart rate variability at respiratory frequencies. The age at onset of autonomic failure was also helpful to predict future diagnosis. Onset of autonomic failure in the early 50s made the diagnosis of MSA more likely, whereas onset of autonomic failure in the mid-60s made phenoconversion to PD/DLB more likely. Similar to our findings in patients with autonomic failure, in patients with idiopathic RBD, the presence of orthostatic hypotension or hyposmia increased the risk of phenoconversion to PD or DLB. 18, 19, [43] [44] [45] Our prospective data support the recently defined research criteria FIGURE 3: Relationship between olfaction, plasma norepinephrine (NE) levels in the supine position (top), and heart rate (HR) response after 3 minutes of head-up tilt (bottom).
Patients with autonomic failure who were later diagnosed with multiple system atrophy (MSA; red) had normal olfactory function, tended to have plasma norepinephrine levels that were not low, and had greater chronotropic response to head-up tilt. Those who converted to PD or dementia with Lewy bodies (DLB; gray) had impaired olfaction, tended to have lower norepinephrine levels, and had a lesser heart rate response to tilt. Patients who remained as pure autonomic failure (PAF) without signs of central nervous system involvement are shown in white. Circles represent clusters of patient groups. PD 5 Parkinson disease; UPSIT 5 University of Pennsylvania Smell Identification Test.
for prodromal PD. 52 Until now, studies of predictive biomarkers for the development of MSA have been limited to retrospective series. 6, 53 Our study has limitations; pathological confirmation is lacking, probable RBD was identified only through questionnaires in most cases, and other cognitive screening instruments may be more sensitive to detect earlier cognitive impairment. The patient cohort was captured 5 years after the onset of autonomic failure, which raises the possibility that the earlier MSA phenoconverters may be under-represented. Neither metaiodobenzylguanidine nor dopamine transporter-single photon emission computed tomography was performed.
It is tempting to speculate that patients who remain as PAF may have a neuroprotective advantage that prevents CNS involvement in the pathological process. Alternatively, it may just be a matter of time before they phenoconvert to a manifest CNS synucleinopathy.
